Juniper Pharmaceuticals, Inc.

Total Valuation

Juniper Pharmaceuticals, Inc. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 77.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Juniper Pharmaceuticals, Inc. currently has 11.11M shares outstanding.

Valuation Ratios

Juniper Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 762.61. The price-to-sales ratio is 1.71, and the price-to-book ratio stands at -0.41.

Enterprise Valuation

On an enterprise value basis, Juniper Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 415.77 and an EV/FCF ratio of 10.22. The EV/Sales ratio of 1.40 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.77 provides insight into valuation relative to core operating earnings.

Financial Position

Juniper Pharmaceuticals, Inc. maintains a current ratio of 2.57, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Juniper Pharmaceuticals, Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 10.80, while the 200-day moving average is 8.52.

Income Statement

Over the trailing twelve months, Juniper Pharmaceuticals, Inc. generated 55.61M in revenue and converted that into -985,000.00 in net income, yielding earnings per share of -0.09. EBITDA reached 187,000.00, while operating income came in at -2.20M.

Balance Sheet

Juniper Pharmaceuticals, Inc. holds 20.83M in cash and equivalents against 3.45M in total debt, resulting in a net debt position of -17.37M. Total book value stands at -233.68M, with working capital of 25.10M providing operational flexibility.

Cash Flow

Juniper Pharmaceuticals, Inc. produced 3.08M in operating cash flow over the past twelve months. After subtracting -4.53M in capital expenditures, free cash flow totaled -1.45M - equivalent to -0.13 per share.

Margins

Juniper Pharmaceuticals, Inc. operates with a gross margin of 40.84, reflecting its pricing power and cost economics. The operating margin of -3.96 and net profit margin of -1.77 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -0.71 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Juniper Pharmaceuticals, Inc.'s most recent stock split took place on August 9, 2013 with a 8:1 split ratio.

Scores

Juniper Pharmaceuticals, Inc. posts an Altman Z-Score of -1.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.